{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "ORIC",
  "name": "Oric Pharmaceuticals, Inc.",
  "url": "https://frontierpicks.com/dossiers/ORIC/",
  "json_url": "https://frontierpicks.com/dossiers/ORIC.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is undated enozertinib 2H-2026 readouts. Range-bound $7–15 tape; build on weakness, not a breakout chase at $10.73.",
  "invalidation_trigger": "A weekly close below $8.50 gives back the post-Phase-3-initiation advance and re-enters the lower half of the 52-week range; a disappointing enozertinib 2H-2026 readout or a pre-Phase-3 capital raise would confirm the break.",
  "catalyst_date": "2026-09-12",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-08-04",
  "invalidation_fired": false,
  "themes": [
    "oncology-immunology",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Naming: rinzimetostat = former ORIC-944 (oral PRC2 inhibitor); enozertinib = former ORIC-114 (brain-penetrant EGFR/HER2). News appears under either name.",
    "Himalayas-1, initiated 2026-07-14, has an rPFS primary endpoint reading out around 2028; the trial start and its ESMO trial-in-progress poster are not efficacy datapoints.",
    "Bayer supplies darolutamide at no cost with no license or option on rinzimetostat; ORIC retains full global rights. J&J supplies subcutaneous amivantamab for the combination arm.",
    "An at-the-market equity program is in use: $59.9M raised as disclosed in the 2026-08-03 Q2 release. Share count moves between filings.",
    "No product revenue. Funded by $387.6M in cash, equivalents and investments at 2026-06-30, with runway guided into 2H 2028."
  ],
  "body_markdown": "## Current Thesis\nTwo things moved since the mid-August update. First, the lung readout acquired a fixed clock: the company's 2026-07-20 release scheduled the enozertinib Phase 1b poster in treatment-naive EGFR-atypical NSCLC (abstract 2627P) for Monday 2026-10-26, 12:00–12:45 CET at ESMO Congress 2026 in Madrid, with all abstracts published publicly on 2026-10-19. Second, price took out its prior high while that wait runs. The 2026-08-21 close was $14.20 against a 52-week high of $14.65, 3.1% below it, versus a $14.41 high and a $13.87 close one week earlier; RSI(14) went from 64.1 to 74.7 across that week on a three-month price change of +70.7%. The leg being bought is a brain-penetrant EGFR inhibitor with an October date attached and a PRC2 prostate asset whose registrational endpoint reads out around 2028. Between 2026-08-21 and 2026-10-19 there is no company-confirmed information event — the re-rating is running on schedule and sell-side revision, with the evidence still two months out.\n\n## Bull Case\n- **The efficacy event is now a calendar entry, not a guidance phrase.** The 2026-07-20 release names three ESMO posters: enozertinib 2627P (2026-10-26), the Himalayas-1 trial-in-progress poster 2303TiP (2026-10-23, 15:15–16:00 CEST) and a rinzimetostat mechanistic ePoster (1128eP). Abstract text goes public 2026-10-19, a week ahead of the enozertinib session.\n- **The grading bar is already published by the company.** At ESMO Asia 2025 the Phase 1b showed 67% ORR in 1L EGFR exon 20, 80% ORR in 1L EGFR PACC and 100% intracranial ORR in both populations among patients with measurable CNS disease. October's poster is readable against those marks.\n- **Registrational design is running.** Himalayas-1, initiated 2026-07-14, enrolls ~600 post-abiraterone mCRPC patients 1:1, rPFS primary with OS a key secondary, rinzimetostat 400 mg once daily, 250+ sites in 25 countries. Bayer supplies darolutamide at no cost and takes no license, option or rights to the asset.\n- **Balance sheet covers the wait.** $387.6M in cash, cash equivalents and investments at 2026-06-30, with runway guided into 2H 2028 and past the first Phase 3 primary readout (2026-08-03 release).\n- **Targets moved with the tape.** H.C. Wainwright maintained Buy and raised its target to $27 from $25 (reported 2026-08-10); aggregator consensus was quoted at $19.27 on 2026-08-12 across roughly fifteen covering firms.\n\n## Bear Case\n- **The advance since 2026-08-10 has no new clinical input behind it.** The last dated company disclosure was the 2026-08-03 quarter; the last third-party datapoint was the 2026-08-10 target raise. The new 52-week high at $14.65 and RSI(14) of 74.7 at the 2026-08-21 close were set in an empty news window.\n- **September looks thin.** WCLC 2026 runs 2026-09-12 to 2026-09-15 in Seoul; per IASLC's own calendar, abstract titles went public 2026-07-31 and the full program on 2026-08-19. Searches through 2026-08-23 surfaced no ORIC release tied to WCLC, while the company did issue a dedicated release for ESMO on 2026-07-20. That is an inference from an absence, not a company statement, but it points at October rather than September for the 1L exon 20 monotherapy and subcutaneous-amivantamab combination data still carried as \"2H 2026\".\n- **The quarter missed and the burn stepped up.** Q2 2026 EPS of $(0.38) against a $(0.36) consensus; Q2 net loss $41.5M; six-month R&D $67.7M versus $55.2M a year earlier; six-month net loss $77.3M (2026-08-03).\n- **The issuance mechanism is live and drawn.** $59.9M raised through an at-the-market program as disclosed 2026-08-03, with weighted-average shares of 106.7M. A stock 3.1% under its 52-week high is the natural window for more of it.\n- **Mechanism and field risk are unresolved.** PRC2 inhibition has no approved precedent in mCRPC and Himalayas-1 rPFS is a ~2028 event; enozertinib must differentiate on CNS penetration and tolerability against amivantamab and the rest of the EGFR exon 20 / atypical field, and the ESMO Asia response rates are single-arm Phase 1b.\n\n## Setup & Price Structure\n- Reference close 2026-08-21: $14.20, with a 52-week high of $14.65 and price 3.1% under it. The high itself is new — coverage a week earlier carried $14.41 as the high and $13.87 as the last close, so the range top was taken out in the week to 2026-08-21.\n- RSI(14) at 74.7 on 2026-08-21 against 64.1 on 2026-08-14. The three-month price change is +70.7%.\n- The pre-announcement shelf sits at the 2026-07-17 close of $10.73, the last print before the 2026-07-20 ESMO release. Everything above that is post-scheduling advance, not post-data advance.\n- The narrative is **accelerating**. What dates it: fresh 52-week highs in the week to 2026-08-21, a target raise to $27 on 2026-08-10, and an RSI push through 70 in the same window. The qualifier is that the acceleration is in attention and scheduling; the next clinical input is 2026-10-19.\n- Crowding and positioning observables, stated as observables: RSI(14) 74.7, above the conventional 70 line; price within 3.1% of its 52-week high; a live at-the-market program with $59.9M already drawn as of 2026-08-03; sell-side targets clustered well above spot ($27 high mark, $19.27 aggregator consensus quoted 2026-08-12); no earnings print inside 30 days; no Form 4 or follow-on prospectus surfaced in the filings and news reviewed through 2026-08-21.\n\n## Catalyst Calendar (next 30 days)\n- **2026-09-12 to 2026-09-15 — WCLC 2026, Seoul.** Company participation unconfirmed as of 2026-08-23; the full program was released 2026-08-19. If the meeting closes without an ORIC presentation, the information vacuum runs to 2026-10-19.\n- **No company-confirmed ORIC event falls inside the next 30 days.** The nearest confirmed dates sit just outside it: 2026-10-19 (ESMO abstracts public), 2026-10-23 (Himalayas-1 poster 2303TiP), 2026-10-26 (enozertinib poster 2627P).\n- **~2026-11-05 (est.) — Q3 2026 results.** Next disclosure of cash against the $387.6M at 2026-06-30 and of any at-the-market issuance beyond $59.9M.\n\n## What Would Change Our Mind\nThe structural break is the post-scheduling advance unwinding: the move from the 2026-07-17 close of $10.73 to $14.20 was paid for by a calendar entry, so losing that shelf would say the market stopped paying for the October date. A weekly close below $10.73 is the gradeable version of that.\n\nOn the fundamentals, three observables would change the read. Abstract text on 2026-10-19 showing 1L EGFR-atypical ORR or intracranial ORR below the company's own ESMO Asia 2025 marks of 80% and 100%, or a discontinuation-driving tolerability signal, removes the differentiation claim the lung program rests on. A 424B5 or underwritten follow-on priced while the stock sits near $14.65 converts strength into supply and marks the issuance risk as realised. And WCLC closing 2026-09-15 with no ORIC presentation confirms that nothing resolves before late October, which makes the current RSI reading a positioning question rather than an information question.\n\nOn the other side, an ORIC abstract appearing on the WCLC program with the exon 20 monotherapy or SC-amivantamab combination data would pull the first real evidence forward by five weeks and change the shape of the wait.\n\n## Correlation Notes\n- Unprofitable, pre-revenue oncology with a 2028 primary endpoint trades with small-cap biotech risk appetite (XBI) and with rate expectations, since the entire valuation is terminal. Neither is company-specific and neither is graded here.\n- J&J sits on both sides: amivantamab is the incumbent in EGFR exon 20 that enozertinib must beat on CNS activity and tolerability, and J&J supplies subcutaneous amivantamab for the combination arm. Competitive data from that franchise reads directly onto the ORIC lung thesis.\n- Bayer's darolutamide franchise is the supply partner for Himalayas-1 (free drug, no rights taken), so darolutamide label and commercial news is adjacent context for the prostate program without being a direct driver.\n- ESMO Congress 2026 (2026-10-23 to 10-27, Madrid) clusters the oncology calendar into one week, with abstracts dropping 2026-10-19. Sector-wide flow and headline competition in that window can dominate a single small-cap poster's reception.",
  "first_seen": "2026-07-15",
  "last_analyzed": "2026-08-23T14:58:12+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}